文献速递淋巴瘤

ctDNA 编码的分子特征揭示高危侵袭性 B 细胞淋巴瘤的异质性并预测结局

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

本研究在接受统一治疗的高危弥漫大 B 细胞淋巴瘤(DLBCL)试验队列中评估液体活检的转化意义。治疗前 ctDNA 揭示隐藏的临床与生物学异质性,高 ctDNA 负荷独立于常规危险因素预测复发和死亡风险增加;治疗中化疗难治性淋巴瘤 ctDNA 动力学出现分化,治疗结束时 MRD 阴性者治愈并解决假残留 PET 阳性等临床疑问;治疗结束时的片段化模式可通过机器学习预测结局。

要点

  • 治疗前高 ctDNA 负荷独立于常规危险因素预测高危 DLBCL 复发和死亡风险增加。
  • 治疗前 ctDNA 基因组分析提供超越诊断性组织活检的分子与预后信息。
  • 治疗结束时 MRD 阴性可识别治愈患者并解释假残留 PET 阳性等临床疑问。

核心结论

  • 液体活检中的新型分子决定因素可无创指导治疗决策。

研究设计与样本

  • 研究为在接受统一治疗的试验队列中评估液体活检转化意义的研究。

主要发现

  • 治疗前 ctDNA 揭示隐藏的临床与生物学异质性,高 ctDNA 负荷独立于常规危险因素预测复发和死亡风险增加。
  • 治疗前 ctDNA 基因组分析揭示超越诊断性组织活检的翻译相关表型、分子和预后信息。
  • 治疗中化疗难治性淋巴瘤显示分化的 ctDNA 动力学,治疗结束时 MRD 阴性识别治愈患者并解决假残留 PET 阳性等临床疑问。
  • 发现淋巴瘤来源 ctDNA 的 cfDNA 片段化差异,机器学习显示治疗结束时片段化模式预测结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized therapeutic options. We studied the translational significance of liquid biopsy in a uniformly treated trial cohort. Pretreatment circulating tumor DNA (ctDNA) revealed hidden clinical and biological heterogeneity, and high ctDNA burden determined increased risk of relapse and death independently of conventional risk factors. Genomic dissection of pretreatment ctDNA revealed translationally relevant phenotypic, molecular, and prognostic information that extended beyond diagnostic tissue biopsies. During therapy, chemorefractory lymphomas exhibited diverging ctDNA kinetics, whereas end-of-therapy negativity for minimal residual disease (MRD) characterized cured patients and resolved clinical enigmas, including false residual PET positivity. Furthermore, we discovered fragmentation disparities in the cell-free DNA that characterize lymphoma-derived ctDNA and, as a proof-of-concept for their clinical application, used machine learning to show that end-of-therapy fragmentation patterns predict outcome. Altogether, we have discovered novel molecular determinants in the liquid biopsy that can noninvasively guide treatment decisions.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Meriranta L, Alkodsi A, Pasanen A, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022. PMID: 34932792. doi:10.1182/blood.2021012852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。